EP3463374A4 - A long acting pharmaceutical composition of protease inhibitor - Google Patents

A long acting pharmaceutical composition of protease inhibitor Download PDF

Info

Publication number
EP3463374A4
EP3463374A4 EP16904195.1A EP16904195A EP3463374A4 EP 3463374 A4 EP3463374 A4 EP 3463374A4 EP 16904195 A EP16904195 A EP 16904195A EP 3463374 A4 EP3463374 A4 EP 3463374A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
protease inhibitor
long acting
acting pharmaceutical
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16904195.1A
Other languages
German (de)
French (fr)
Other versions
EP3463374A1 (en
Inventor
James Nienyuan CHANG
Hsiang-Fa Liang
Meng-Hsin Chen
Kuei-Ling Kuo
An-Chieh Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taimed Biologics Inc
Original Assignee
Taimed Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taimed Biologics Inc filed Critical Taimed Biologics Inc
Publication of EP3463374A1 publication Critical patent/EP3463374A1/en
Publication of EP3463374A4 publication Critical patent/EP3463374A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16904195.1A 2016-05-31 2016-05-31 A long acting pharmaceutical composition of protease inhibitor Withdrawn EP3463374A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/035029 WO2017209732A1 (en) 2016-05-31 2016-05-31 A long acting pharmaceutical composition of protease inhibitor

Publications (2)

Publication Number Publication Date
EP3463374A1 EP3463374A1 (en) 2019-04-10
EP3463374A4 true EP3463374A4 (en) 2020-01-22

Family

ID=60478957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16904195.1A Withdrawn EP3463374A4 (en) 2016-05-31 2016-05-31 A long acting pharmaceutical composition of protease inhibitor

Country Status (4)

Country Link
EP (1) EP3463374A4 (en)
JP (1) JP6704058B2 (en)
CN (1) CN109475563A (en)
WO (1) WO2017209732A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068858A (en) * 1997-02-13 2000-05-30 Elan Pharma International Limited Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2539527T3 (en) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Method for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors
CA2632095A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
ES2511790T3 (en) * 2006-05-30 2014-10-23 Janssen R&D Ireland Lysine-related derivatives such as HIV aspartyl protease inhibitors
CL2007001847A1 (en) * 2006-06-23 2008-02-08 Tibotec Pharm Ltd INTRAMUSCULAR OR SUBCUTANEOUS PHARMACEUTICAL COMPOSITION INCLUDING TMC278 (RILPIVIRINE); PROCESS TO PREPARE THE COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF HIV INFECTION.
EP2109461A2 (en) * 2006-07-17 2009-10-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068858A (en) * 1997-02-13 2000-05-30 Elan Pharma International Limited Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAS MALAY K ET AL: "Nano-ART and NeuroAIDS", DRUG DELIVERY AND TRANSLATIONAL RESEARCH, SPRINGER, GERMANY, vol. 6, no. 5, 2 May 2016 (2016-05-02), pages 452 - 472, XP036042525, ISSN: 2190-393X, [retrieved on 20160502], DOI: 10.1007/S13346-016-0293-Z *
LALIT KUMAR ET AL: "Nanotechnology: A magic bullet for HIV AIDS treatment", ARTIFICIAL CELLS, NANOMEDICINE AND BIOTECHNOLOGY, vol. 43, no. 2, 25 February 2014 (2014-02-25), US, pages 71 - 86, XP055653795, ISSN: 2169-1401, DOI: 10.3109/21691401.2014.883400 *
See also references of WO2017209732A1 *

Also Published As

Publication number Publication date
CN109475563A (en) 2019-03-15
WO2017209732A1 (en) 2017-12-07
JP6704058B2 (en) 2020-06-03
EP3463374A1 (en) 2019-04-10
JP2019510002A (en) 2019-04-11

Similar Documents

Publication Publication Date Title
IL266146A (en) Piperidine derivatives as inhibitors of ubiquitin specific protease
IL273842A (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
EP3541932A4 (en) Inhibitors of crispr-cas9
EP3246317A4 (en) Btk inhibitor
HK1256256A1 (en) Pharmaceutical composition comprising a potent inhibitor of urat1
EP3447058A4 (en) Novel broad-spectrum -lactamase inhibitor
EP3194369A4 (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
EP3261639A4 (en) Substituted pyrazole compounds as serine protease inhibitors
EP3171859A4 (en) Pharmaceutical composition comprising 5alpha-reductase inhibitor
EP3415146A4 (en) Inflammasome activation inhibitor
EP3142659A4 (en) Hiv-1 protease inhibitors and uses thereof
EP3558305A4 (en) Heterocyclic compounds as hiv protease inhibitors
EP3116862A4 (en) Piperazine derivatives as hiv protease inhibitors
EP3562487A4 (en) Metalloenzyme inhibitor compounds
EP3429589A4 (en) Pharmaceutical composition of nilotinib
EP3113780A4 (en) Hiv protease inhibitors
EP3524250A4 (en) Pharmaceutical composition
EP3342765A4 (en) Cathepsin k inhibitor and application thereof
EP3705471A4 (en) Double-headed protease inhibitor
EP3192794A4 (en) Sustained hiv protease inhibitor
EP3562306A4 (en) Metalloenzyme inhibitor compounds
EP3493808A4 (en) Pharmaceutical compositions of ibrutinib
EP3097084A4 (en) New kallikrein 7 inhibitors
EP3337567A4 (en) Hiv-1 protease inhibitors and uses thereof
EP3104705A4 (en) Cathepsin cysteine protease inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180716

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031551000

Ipc: A61K0031630000

A4 Supplementary search report drawn up and despatched

Effective date: 20200107

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/661 20060101ALI20191219BHEP

Ipc: A61K 31/63 20060101AFI20191219BHEP

Ipc: A61K 9/10 20060101ALI20191219BHEP

Ipc: A61P 31/18 20060101ALI20191219BHEP

Ipc: A61K 9/00 20060101ALI20191219BHEP

Ipc: A61K 9/51 20060101ALI20191219BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230205